 |
 |
|
January 11: Dr. Louis M. Staudt, Chief, Lymphoid Malignancies Section, Metabolism Branch, CCR, "Molecular Diagnosis and Molecular Targets in Lymphoid Malignancies by Gene Expression Profiling"
January 18: Dr. Beverly Teicher, Vice President, Oncology Research, Genzyme Corporation, "Newer Cell-based Models and Therapeutic Targets Related to Tumor Vasculature"
CCR Grand Rounds are held 8:30 to 9:30 a.m. at the NIH campus in Bethesda, Md., in the Clinical Center's Lipsett Amphitheater.
|
|
Logothetis Discusses New Opportunities for Prostate Cancer Therapy
On December 14, Dr. Christopher Logothetis, director of the M.D. Anderson Cancer Center's Genitourinary Center, visited NIH to discuss "Biological Basis for the Development and Application of Therapy for Prostate Cancer." Dr. Logothetis outlined several key research projects at the genitourinary center, including the role of fat tissue as an endocrine organ in the development of prostate cancer among obese men (with relapse trends after surgery); analysis of small prostate tissue samples using laser-capture microdissection followed by RNA extraction and gene expression profiling; treatments that target metastatic cancer sites without affecting the primary tumor, effectively neutering the malignancy and rendering it more vulnerable to surgical elimination; and the extended survival seen in patients who undergo serial chemotherapy treatments. Dr. Logothetis presented prepublication data from several ongoing clinical trials, and emphasized his team's integrative strategy for analyzing the basic biology of prostate cancer and translating this into improved disease diagnosis and treatment.
NCI Web Site Rated Best E-Government Main Site
The American Customer Satisfaction Index (ACSI), used by the federal government and the private sector to measure citizen satisfaction with the quality of goods and services, has rated http://www.cancer.gov first in citizen satisfaction in the E-Government Portals/Department Main Web Sites category. The redesigned Web site was ranked first in the 2004 fourth-quarter ratings. The December 14 report announcing the first-place standing stated that the portals in the index face the challenging task of catering to a wide range of constituents - in this case, patients and their families, health professionals, researchers, and advocates, among others. ACSI is produced by the University of Michigan, in partnership with the American Society for Quality, ForeSee Results, and the CFI Group.
NCI Director on WJFK-FM
On Saturday, January 8 at 9:00 a.m. on WJFK-FM (106.7), NCI director Dr. Andrew C. von Eschenbach will appear on "The Business of Government Hour." In this interview, Dr. von Eschenbach will discuss NCI's quest to eliminate suffering and death from cancer by 2015. He will discuss the convergence of medical research and technology and the Cancer Biomedical Informatics Grid (caBIG), an informatics infrastructure that allows cancer researchers to better develop and share tools and data in an open environment both nationally and internationally. For listeners outside of the Washington, D.C. area, the interview will be available at http://www.businessofgovernment.org.
NCI Launches Nanotechnology Teaming Web Site
The NCI Alliance for Nanotechnology in Cancer has launched the Nano Teaming Site to serve the growing need within the research community to identify potential areas of collaboration across disciplines, organizations, and sectors. NCI is particularly interested in identifying medical oncologists with backgrounds in technology development.
The Nano Teaming Site contains information on investigators interested in nanotechnology and its application to reducing suffering and death due to cancer. The site comprises a user-driven database that enables researchers to explore partnering opportunities with other participating researchers who have various areas of expertise. Each participant creates a simple profile with contact information, affiliation, and specific area(s) of expertise. Investigators can then search for other researchers with specific areas of expertise in particular organizations, identifying collaborative opportunities across disciplines participating in cancer nanotechnology research and development. As information is gathered, the Nano Teaming Site will be a valuable tool for the cancer research community by facilitating the initial interfaces among investigators across multiple disciplines and sectors.
The Nano Teaming Site is posted on the NCI Alliance for Nanotechnology in Cancer Web site at http://nano.cancer.gov.
|
